ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60

RESMED INC

2025-FY EPS reported $9.51 revenue$5,146,327,000

Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).
Gross margin up 230bps to 60.8% GAAP; operating income $454.5M (+19%).
FY2025 revenue $5.15B (+10%); GAAP EPS $9.51 (+37%).
Dividend raised 13% to $0.60/share; payable Sept 18, record Aug 14; ex-div Aug 13.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.